Analysis of Interaction between Twenty-Seven Pyrimidinone Derivatives with XIAP Using a Theoretical Model

IF 0.1
L. Figueroa-Valverde, F. Díaz-Cedillo, M. Rosas-Nexticapa, Catalina Cervantes-Ortega, Magdalena Alvarez-Ramirez, Virginia Mateu-Armand, M. Lopez-Ramos
{"title":"Analysis of Interaction between Twenty-Seven Pyrimidinone Derivatives with XIAP Using a Theoretical Model","authors":"L. Figueroa-Valverde, F. Díaz-Cedillo, M. Rosas-Nexticapa, Catalina Cervantes-Ortega, Magdalena Alvarez-Ramirez, Virginia Mateu-Armand, M. Lopez-Ramos","doi":"10.51847/2bwwpf0bdl","DOIUrl":null,"url":null,"abstract":"For several years, several drugs have been used to treat different types of cancer; however, some of these drugs can cause side effects, such as high blood pressure, liver damage, and erectile dysfunction. In the search for new therapeutic alternatives, some compounds have been developed for the treatment of this clinical pathology; however, the interaction of these drugs with some biomolecules involved in the development of cancer is very unclear. Analyzing this data, this investigation aimed to evaluate the possible theoretical interaction of some pyrimidinone derivatives (compounds 1 to 27) on the X-linked inhibitor of apoptosis protein (XIAP) involved in cancer using the Docking model. The results showed that some pyrimidinone derivatives (1-6, 10, 11, 14, 15, 22-24, 26, and 27) could interact with the XIAP protein surface. In conclusion, these data suggest that some pyrimidinone derivatives can produce changes in the biological activity of XIAP. Therefore, these pyrimidinone derivatives could be good candidates to treat cancer.","PeriodicalId":44457,"journal":{"name":"Clinical Cancer Investigation Journal","volume":"1 1","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cancer Investigation Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51847/2bwwpf0bdl","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

For several years, several drugs have been used to treat different types of cancer; however, some of these drugs can cause side effects, such as high blood pressure, liver damage, and erectile dysfunction. In the search for new therapeutic alternatives, some compounds have been developed for the treatment of this clinical pathology; however, the interaction of these drugs with some biomolecules involved in the development of cancer is very unclear. Analyzing this data, this investigation aimed to evaluate the possible theoretical interaction of some pyrimidinone derivatives (compounds 1 to 27) on the X-linked inhibitor of apoptosis protein (XIAP) involved in cancer using the Docking model. The results showed that some pyrimidinone derivatives (1-6, 10, 11, 14, 15, 22-24, 26, and 27) could interact with the XIAP protein surface. In conclusion, these data suggest that some pyrimidinone derivatives can produce changes in the biological activity of XIAP. Therefore, these pyrimidinone derivatives could be good candidates to treat cancer.
27种嘧啶类衍生物与XIAP相互作用的理论模型分析
几年来,几种药物被用于治疗不同类型的癌症;然而,其中一些药物会引起副作用,如高血压、肝损伤和勃起功能障碍。在寻找新的治疗方案,一些化合物已经开发用于治疗这种临床病理;然而,这些药物与一些参与癌症发展的生物分子的相互作用尚不清楚。分析这些数据,本研究旨在利用对接模型评估一些嘧啶酮衍生物(化合物1至27)与参与癌症的X-linked inhibitor of apoptosis protein (XIAP)可能的理论相互作用。结果表明,一些嘧啶酮衍生物(1-6、10、11、14、15、22-24、26和27)可以与XIAP蛋白表面相互作用。综上所述,这些数据表明,一些嘧啶类衍生物可以改变XIAP的生物活性。因此,这些嘧啶酮衍生物可能是治疗癌症的良好候选者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
8
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信